is an important cause of both pulmonary disease in individuals with underlying lung diseases such as 44 cystic fibrosis and chronic obstructive pulmonary disease and is an opportunistic pathogen in 45 immunocompromised patients (3, 4) . Among the NTM species isolated from U.S. patients, 80% were 46 classified as MAC (5). MAC is ubiquitous within the environment and is found in soil, treated or 47 untreated water, house plumbing systems and animals (6). MAC infection is difficult to treat and has 48 been shown to be resistant to many of the clinically used anti-tuberculosis agents (7, 8) . We previously 49 disclosed a novel family of compounds, imidazo[1,2-a]pyridine-3-carboxamides (IAPs), with potent 50 activity against M. tuberculosis (Mtb) (9-12). The mechanism of action and anti-Mtb in vivo efficacy of 51 this exciting new class has been documented by us and other groups (9, 13-16). Through a "hit" to 52 "lead" optimization effort aided by the Lilly TB Drug Discovery Initiative (LTBDDI) additional IAP 53 compounds (1 -6) were generated and found to have encouraging in vivo pharmacokinetics (PK). 54
Herein, we describe activity of these latest analogs against M. avium both in vitro and in vivo. 55 56 Activity of selected compounds in vitro. Six compounds having diverse PKs were selected and 57 synthesized following our published methods (9-11). Experimental data and information on all 58 previously uncharacterized compounds (1, 2 and 6) can be found in the supporting information section. 59 MIC studies were performed using a resazurin-based colorimetric assay and CFU quantification as 60 described (17). Screening the IAPS against M. avium strains 101 and 2151 using standard protocols 61 indicated that they had moderate potency (Table 1 ). The activity of these compounds against M. avium 62 (2.6 -27.8 µM, two strains) was limited relative to Mtb (Table S1 ) but comparable to positive controls of 63 clarithromycin and azithromycin (1.4 and 13.4 μM, respectively). These compounds also had a good 64 therapeutic window when screened against VERO cells (9) ( Table S1) . 65 4 All six compounds were evaluated for their ability to kill or inhibit M. avium replication in vitro. Five out 66 of six compounds were bactericidal or bacteriostatic (Fig 2) . Consistent with its MIC value, ND-9903 (5) 67 showed no activity against M. avium 101 at the highest concentration tested. Separate studies of ND-68 9758 (3), ND-9759 (4) and ND-10890 (6) at a 1.0 µg/ml each indicated that they were bacteriostatic as 69 the bacterial counts were maintained near the original inoculum. ND-10885 (2) and ND-9873 (1) had 70 bactericidal activity against M. avium 101 at 1.0 µg/ml as bacterial numbers decreased by 1 log 10 and 0.5 71 log 10 , respectively, compared to the original inoculum. Rifampin was the positive control and showed 72 the best bactericidal activity against M. avium 101. Except for ND9903 (9), all compounds showed dose-73 dependent activity against M. avium. ND-10885 (2) also showed activity against various other M. avium 74 clinical isolates of different serotypes, although again it varied 10 fold or more between strains. 75
Pharmacokinetics. Single-dose pharmacokinetics of compounds 1 -6 were determined in uninfected 8-76
week-old male Balb/c mice. Mice received by oral gavage a single dose of compound 1 (at 10 and 100 77 mg/kg), compound 2 (at 100 mg/kg) , compound 3 (at 10 mg/kg), compound 4 (at 30 mg/kg), compound 78 5 (at 100 mg/kg), and compound 6 (at 10 and 100 mg/kg). Compounds were analyzed as previously 79 described (10). Calculated parameters include clearance (Cl), area-under-the-curve (AUC), half-life 80 (T1/2), maximum serum concentration (Cmax), time of maximum concentration (Tmax), bioavailability 81 (%F) and percent drug fraction unbound in plasma (Fu, Plasma). 82
As shown in table 2, all of these compounds had high plasma exposure at their respective doses but 83 there was a large range in half-lives observed (from 2.3 to >24 h). In our drug development paradigm, 84
we selected the maximum free drug concentration per dose (Cmax, u) as the most meaningful 85 pharmacokinetic property to use for compound advancement and ND-10885 (2) and ND-10890 (6) had 86 the highest values (2,795 and 4,232 nM, respectively). The free drug concentration for those two 87 compounds were high enough above their MICs that they were anticipated to be effective against MAC 88 5 Maximum tolerated dose. Five compounds were evaluated in mice to determine their maximum 90 tolerated dose as previously described (13). Compounds ND-9873 (1) and ND-10885 (2) were tolerated 91 at the highest concentration of 250 mg/kg for one week, ND-10890 (6) was well-tolerated at 100 mg/kg 92 for one week and as previously reported ND-9759 (5) was tolerated at 30 mg/kg for 28 days (13). Mice 93 treated with ND-9758 (3) did not tolerate the drug even at the lowest concentration (30 mg/kg). 94
Efficacy of ND10885 in MAC-infected mice. We chose compound ND-10885 (2) for the in vivo studies in 95
Wild type Balb/c mice based on its relatively good in vitro bactericidal activity against M. avium, its PK 96 profile and its low toxicity in mice. Wild type Balb/c mice (n=3) were retro-orbitally infected with M. 97 avium MAC 101 at a dose of 10 7 CFU in 50 µL of PBS (18). One week after the infection, mice were 98 treated by oral gavage with ND-10885 (2) dissolved in 80% propylene glycol (v/v) once daily 6 days a 99 week for two weeks. After the final dosing, all mice were sacrificed, and the mycobacaterial burden was 100 determined as described previously (13). The bacterial numbers were quantified by visually counting 101 bacterial colonies. At the beginning of treatment, a group of mice (n=3) were sacrificed to measure the 102 mycobacterial input in the lung, spleen and liver. As a negative control, a group of mice (n=3) were 103 treated with the vehicle, 80% propylene glycol, only. 104 ND-10885 (2) significantly inhibited M. avium growth in the lungs, spleens and livers when compared to 105 the vehicle-treated M. avium-infected mice (Fig 3) . The inhibitory activity of ND-10885 (2) was 106 comparable to that of rifampin in all three organs. In addition, compared to single compound/drug 107 regimens, mycobacterial counts were lower in all three organs when M. avium-infected mice were 108 treated with a combined regimen of ND-10885 (2) and rifampin, although this was only statistically 109 significant in the lung. When compared with baseline mycobacterial counts at the initiation of 110 treatment, the combined regimen showed bactericidal activity with the CFU count decreasing 1.5-fold 111 (Log 10 ) in the lung. on June 20, 2016 by UNIV OF NOTRE DAME
